Search Results

Otsuka Pharmaceutical Co., Ltd. and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc. announce termination of development of the novel compound AVP-786, which was in development as a potential treatment for patients with agitation associated with dementia due to Alzheimer’s disease.

Ionis Pharmaceuticals, Inc. announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. under which Otsuka obtains exclusive rights across the Asia-Pacific region for donidalorsen, an investigational RNA-targeted prophylactic medicine for hereditary angioedema.

Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and Click Therapeutics, Inc., (Click) announce that the U.S. Food and Drug Administration (FDA) has cleared Rejoyn.

Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announce the U.S. Food and Drug Administration (FDA) has determined that the supplemental New Drug Application (sNDA) for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD) is sufficiently complete to permit a substantive review. The FDA has assigned the application for a Prescription Drug User Fee Act (PDUFA) target action date of February 8, 2025.

Britannia selling its UK lab and testing business to a private UK-based acquiror for total enterprise value of up to £24.2 million (CAD$43.6 million) Initial consideration of £18.7 million (CAD$33.7 million) payable in cash on closing Additional consideration of up to £5.5 million (CAD$9.9 million) payable contingent on achieving certain EBITDA targets at March 2025 and December 2025. After the disposition Britannia will be debt free with assets that consist of significant cash reserves, and shares in Britannia Mining Solutions and Cosmetics Lab

With an upfront $800 million payment and $325 million in potential milestones, Otsuka Pharmaceutical is acquiring Jnana Therapeutics’ drug discovery platform and rare disease candidate, the companies announced Thursday.

Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s greenlight for an injectable formulation of BMS’s cancer blockbuster.

TauRx Pharmaceuticals Ltd has announced the submission of a UK Marketing Authorisation Application for hydromethylthionine mesylate for treatment of mild cognitive impairment and mild to moderate stages of dementia due to Alzheimer’s disease.

Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC) and our parent company Otsuka Pharmaceutical, Co. Ltd. (Otsuka) announce topline results of the phase 3 clinical trial of AVP-786 in the treatment of agitation associated with dementia due to Alzheimer’s disease (Trial 17-AVP-786-305; NCT03393520).